MOSCOW (MRC) -- The global medical composite materials market is estimated to register a CAGR of 6.91% by 2020, as per Plastemart with reference to Research and Markets.
Commenting on the report, an analyst from the research team said: Increased demand for prosthetics and orthotics will be a key trend for market growth. Individuals with damages in their limbs due to accidents or diseases have led to a rise in the demand for artificial limbs made from composite materials.
Even though carbon fiber and fiberglass have high tensile strength, they are brittle and hence cannot be used as prosthetic socket materials. This has resulted in the use of nylon, polyester, and acrylic and epoxy resins in the manufacture of prosthetics and orthotics. The adhesive and mechanical properties of the resins and fibers influence the performance of these products.
According to the report, emergence of lightweight and heat-resistant composites will be a key driver for market growth. Polymer composites are lightweight and heat resistant, and hence can be used as alternatives to metals and alloys. Polymer matrix composites have been used in the manufacture of medical prostheses and implants over the last decade. These composites are divided into reinforced plastics and advanced composites. Advanced composites contain approximately 60% of resistant continuous fibers made of carbon, glass, or aramid materials. They are increasingly being used in medical equipment such as surgical instruments, orthopedic products, and biocompatible implants.
As MRC wrote before, Clariant, a world leader in specialty chemicals, has recently introduced MEVOPUR-LQ, a family of color and additive solutions that combines the benefits of the MEVOPUR 'controlled, consistent and compliant' formulation and manufacturing approach with Clariant’s Hi Former liquid-vehicle technology. Initial product releases include a transparent amber color concentrate suitable for polyethylene terephthalate (PET and PETG) materials typically used in pharmaceutical packaging, and color and additive concentrates formulated for liquid silicone resin (LSR). The major benefit of these concentrates is that the ingredients used in the formulation of the concentrates, are evaluated according to USP<87>,<88> and ISO10993 and other relevant industry standards, thereby helping to reduce the risk of interaction with the body and/or the drug.
MRC